

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zhaoke Ophthalmology Limited

兆科眼科有限公司

(Incorporated in the British Virgin Islands with limited liability and continued in the Cayman Islands)

(Stock Code: 6622)

PROFIT ALERT – REDUCTION IN LOSS

This announcement is made by Zhaoke Ophthalmology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to (i) Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”), and (ii) the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Directors**”) of the Company (the “**Board**”) wishes to inform the shareholders and potential investors of the Company that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended June 30, 2024 and assessment of the latest information currently available, the Board expects the Group to record a loss for the period of no more than RMB77 million for the six months ended June 30, 2024 as compared a loss for the period of approximately RMB233.7 million for the corresponding period in 2023.

Based on the information currently available to the Board, the expected reduction in loss for the period is mainly due to (i) the milestone payment we received in the first half of 2024 pursuant to a product license agreement; (ii) the decrease in research and development expenses associated with NVK002 and TAB014 for the six months ended June 30, 2024 as the Phase III clinical trials for such two drug candidates are close to completion; and (iii) increased revenue contribution from the sales of ophthalmic drugs (including Bimatoprost Timolol and Eyprotor) for the six months ended June 30, 2024.

The information contained in this announcement is only based on the preliminary assessment of unaudited consolidated management accounts and relevant revenue estimates made available to the Board as at the date of this announcement, which have not been audited or reviewed by the Company’s auditors or reviewed by the audit committee of the Board. The Company is still in the progress of finalizing the interim results of the Group for the six months ended June 30, 2024 and such interim results may be subject to further adjustment(s) and may be different from the information contained in this announcement. The Group’s financial results and performance for the six months ended June 30, 2024 are expected to be published in late August 2024 in compliance with the Listing Rules.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Zhaoke Ophthalmology Limited
Dr. Li Xiaoyi
Chairman

Hong Kong, August 14, 2024

As at the date of this announcement, the Board comprises Dr. Li Xiaoyi and Mr. Dai Xiangrong as executive Directors; Ms. Leelalertsuphakun Wanee and Ms. Tiantian Zhang as non-executive Directors; and Mr. Wong Hin Wing, Prof. Lo Yuk Lam and Mr. Liew Fui Kiang as independent non-executive Directors.